Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polycaprolactone microspheres + recombinant type III humanized collagen + sodium hyaluronate
- Development stage
- Unknown
- Lead developer
- West China Hospital of Stomatology, Sichuan University
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Intradermal, Subcutaneous
01
Overview
This drug is an injectable composite dermal filler consisting of polycaprolactone (PCL) microspheres, recombinant type III humanized collagen, and sodium hyaluronate. It is designed for the correction of temporal depression and other facial volume deficits. The PCL microspheres act as a bio-resorbable scaffold that stimulates long-term endogenous collagen production (neocollagenesis) by fibroblasts. The recombinant type III humanized collagen provides immediate, biocompatible structural support and promotes tissue integration and rejuvenation. Sodium hyaluronate serves as a carrier and provides immediate volumization and hydration. This multi-phasic combination aims to provide both immediate aesthetic improvement and sustained tissue regeneration. It is currently being evaluated in Phase 3 clinical trials in China.
- Other names
- PCL microspheres + recombinant type III humanized collagen-sodium hyaluronate lyophilized fiberPCL-collagen-HA composite filler
02
Targets
Beyond the preview
Go deeper on polycaprolactone microspheres + recombinant type III humanized collagen + sodium hyaluronate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polycaprolactone microspheres + recombinant type III humanized collagen + sodium hyaluronate.